Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actelion Reports $716 Million Global Sales Of Tracleer In First Nine Months Of 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss company is cagey on the impact of Gilead’s PAH product Letairis on sales of Tracleer during its third quarter 2007 earnings call.

You may also be interested in...



Actelion Launches 500-Patient Phase III Trial For Next-Generation PAH Drug

Taking the Actelion-1 compound to market would give Swiss firm an edge in PAH battle with Gilead.

Actelion Launches 500-Patient Phase III Trial For Next-Generation PAH Drug

Taking the Actelion-1 compound to market would give Swiss firm an edge in PAH battle with Gilead.

Letairis Uptake “Excellent” In First Full Quarter, Gilead Exec Says

Sales of the PAH drug, which competes with Actelion’s Tracleer, were around $6 million, but free-month offer is about to end.

Topics

UsernamePublicRestriction

Register

PS065213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel